AstraZeneca Secures FDA Approval for Baxfendy, Targeting $5 Billion Sales
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Source: Yahoo Finance
- Drug Approval: AstraZeneca's hypertension medication Baxfendy has received FDA approval, potentially becoming a significant growth driver with projected annual sales exceeding $5 billion, particularly for patients inadequately treated by existing therapies.
- Market Opportunity: Clinical trials demonstrated that Baxfendy significantly lowers blood pressure when used alongside other antihypertensives, addressing the urgent need for effective treatments among approximately 23 million patients in the U.S. who still struggle with blood pressure control.
- Strategic Acquisition: Baxfendy was acquired through AstraZeneca's $1.8 billion purchase of CinCor Pharma in 2023, highlighting the company's strategic focus on cardiovascular and metabolic diseases while enhancing its competitive position in the rapidly growing weight-loss market.
- Future Prospects: AstraZeneca is also testing Baxfendy for heart failure prevention, which could further propel the company towards its ambitious goal of achieving $80 billion in annual revenue by 2030, reflecting a long-term strategic vision in drug development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AZN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AZN
Wall Street analysts forecast AZN stock price to rise
14 Analyst Rating
13 Buy
0 Hold
1 Sell
Strong Buy
Current: 189.750
Low
157.61
Averages
213.64
High
252.18
Current: 189.750
Low
157.61
Averages
213.64
High
252.18
About AZN
AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Enhertu Recommended for EU Approval as HER2 Targeted Therapy
- Clinical Trial Results: In the DESTINY-PanTumor02 trial, Enhertu achieved a 51.4% objective response rate (ORR) in HER2 positive tumor patients, with a median duration of response of 14.2 months, indicating its potential to transform treatment for patients with limited options.
- Multiple Cancer Indications: Enhertu demonstrated ORRs of 52.9% and 46.9% in DESTINY-Lung01 and DESTINY-CRC02 trials respectively, highlighting its efficacy in non-small cell lung cancer and colorectal cancer, thereby broadening its therapeutic indications.
- Safety Profile: Among 267 patients, Enhertu's safety profile was consistent with previous trials, with the most common adverse events being neutropenia and anemia, each at 10.9%, indicating its acceptability and safety in clinical use.
- Market Outlook: The positive CHMP opinion paves the way for Enhertu's approval in the EU, potentially becoming the first treatment option for HER2 positive metastatic solid tumors, which is expected to significantly enhance Daiichi Sankyo and AstraZeneca's market share in oncology.
See More
AstraZeneca and Daiichi Sankyo's Datroway Approved by FDA for Breast Cancer Treatment
- FDA Approval: AstraZeneca and Daiichi Sankyo's antibody-drug conjugate Datroway has received FDA approval as a first-line treatment for metastatic triple-negative breast cancer, specifically for patients who are not candidates for PD-1/PD-L1 inhibitor therapy, marking a significant advancement in cancer treatment.
- Clinical Trial Data: The approval was based on data from the TROPION-Breast02 phase III trial, which demonstrated that Datroway significantly improves median overall survival compared to traditional chemotherapy, indicating its potential to enhance patient survival rates.
- Priority Review Status: Datroway's new indication received Priority Review, which not only expedited its market entry but also reflects the FDA's recognition of the drug's importance in treating metastatic triple-negative breast cancer, potentially providing new options for patients.
- Market Impact and Outlook: With FDA approval, Datroway is poised to capture a significant share in the competitive oncology market, enhancing AstraZeneca's market position and revenue potential, thereby solidifying its leadership in the biopharmaceutical sector.
See More
AstraZeneca and Daiichi Sankyo Launch Datroway for TNBC Treatment
- FDA Approval: AstraZeneca and Daiichi Sankyo announced that Datroway (datopotamab deruxtecan) has received FDA approval for the treatment of metastatic triple-negative breast cancer (TNBC), marking a significant advancement in this area and is expected to substantially improve patient survival rates.
- Clinical Trial Results: The TROPION Breast 02 trial, involving 644 TNBC patients who were not candidates for PD-1/PD-L1 inhibitor therapy, demonstrated a clinically meaningful 5-month improvement in median overall survival following treatment with Datroway, indicating its efficacy in extending patient survival.
- Significant Market Potential: With 345,000 new cases of TNBC diagnosed globally each year, accounting for 15% of all breast cancer cases, the launch of Datroway provides a new treatment option for this large patient population, potentially leading to substantial market revenue.
- Future Development Directions: In addition to TNBC, Datroway is also being evaluated for efficacy in non-small cell lung cancer and urothelial cancers, showcasing its broad potential indications and further solidifying AstraZeneca's strategic positioning in the oncology treatment landscape.
See More
EU Drug Regulator Panel Endorses Eight New Medicines for Approval
- New Drug Approvals: The EU drug regulator's expert panel endorsed eight new medicines this week, including Merck's Keytruda and AstraZeneca's Enhertu, indicating a positive outlook for cancer treatment advancements that could enhance market performance for these companies.
- Maviret Indication Expansion: AbbVie announced that its antiviral drug Maviret received a positive opinion for use in patients aged three and older with acute hepatitis C, with final authorization expected by Q3 2026, thereby expanding its influence in the liver disease treatment market.
- Keytruda Combination Therapy: Merck's Keytruda was recommended for use in combination with Pfizer's Padcev for muscle-invasive bladder cancer that cannot be surgically removed, which is expected to enhance its competitive position in the oncology market, with a final decision anticipated by Q3 2026.
- Trodelvy Label Expansion: Gilead's Trodelvy received a positive opinion for treating adults with unresectable triple-negative breast cancer, with a final decision on the label expansion expected later this year, further solidifying Gilead's position in the oncology drug market.
See More
Biotech Sector Regulatory Approvals and Collaborations
- Kidney Cancer Treatment Breakthrough: HUTCHMED and Innovent received NMPA approval in China for the ELUNATE-TYVYT combination therapy, supported by the FRUSICA-2 study showing a 63% reduction in disease progression or death risk, with a median progression-free survival of 22.2 months, significantly improving patient outcomes and enhancing market competitiveness.
- Antibiotic Market Expansion: Sunshine Biopharma received Canadian approval for its generic Amoxicillin, with shipments expected to begin in August 2026, aiming to increase access to high-quality antibiotics for treating common infections, which is anticipated to drive revenue growth for the company.
- Liquid Biopsy Technology Innovation: Guardant Health gained FDA approval for Guardant360 Liquid CDx, now the largest liquid biopsy panel with a genomic footprint 100 times broader than its predecessor, enhancing tumor profiling capabilities and expected to boost the company's market share in precision medicine.
- New Hypertension Drug Launch: AstraZeneca received FDA approval for BAXFENDY for hypertension patients, based on positive results from the BaxHTN Phase III trial, which is expected to strengthen the company's competitive position in the cardiovascular drug market and further expand its product line.
See More
DATROWAY Approved for Treatment of Triple-Negative Breast Cancer
- Significant Survival Extension: In the TROPION-Breast02 Phase III trial, DATROWAY demonstrated an unprecedented median overall survival of approximately two years compared to chemotherapy, indicating its potential to become the new standard of care for patients with unresectable or metastatic triple-negative breast cancer.
- FDA Priority Review Approval: DATROWAY has been approved by the FDA as the first drug to significantly prolong survival in the first-line setting, providing a much-needed treatment option for patients who are not candidates for PD-1/PD-L1 inhibitor therapy, thus filling a critical gap in the market.
- Outstanding Clinical Trial Results: DATROWAY achieved a 64% objective response rate in clinical trials, significantly higher than the 30% seen with chemotherapy, while also reducing the risk of disease progression or death by 43%, establishing a strong foundation for its application in cancer treatment.
- Global Development Program: The global clinical development program for DATROWAY is underway, covering multiple cancer types, showcasing its broad application potential in oncology and further solidifying AstraZeneca and Daiichi Sankyo's leadership in the oncology drug market.
See More
Enhertu Recommended for EU Approval as HER2 Targeted Therapy
- Clinical Trial Results: In the DESTINY-PanTumor02 trial, Enhertu achieved a 51.4% objective response rate (ORR) in HER2 positive tumor patients, with a median duration of response of 14.2 months, indicating its potential to transform treatment for patients with limited options.
- Multiple Cancer Indications: Enhertu demonstrated ORRs of 52.9% and 46.9% in DESTINY-Lung01 and DESTINY-CRC02 trials respectively, highlighting its efficacy in non-small cell lung cancer and colorectal cancer, thereby broadening its therapeutic indications.
- Safety Profile: Among 267 patients, Enhertu's safety profile was consistent with previous trials, with the most common adverse events being neutropenia and anemia, each at 10.9%, indicating its acceptability and safety in clinical use.
- Market Outlook: The positive CHMP opinion paves the way for Enhertu's approval in the EU, potentially becoming the first treatment option for HER2 positive metastatic solid tumors, which is expected to significantly enhance Daiichi Sankyo and AstraZeneca's market share in oncology.
See More
AstraZeneca and Daiichi Sankyo's Datroway Approved by FDA for Breast Cancer Treatment
- FDA Approval: AstraZeneca and Daiichi Sankyo's antibody-drug conjugate Datroway has received FDA approval as a first-line treatment for metastatic triple-negative breast cancer, specifically for patients who are not candidates for PD-1/PD-L1 inhibitor therapy, marking a significant advancement in cancer treatment.
- Clinical Trial Data: The approval was based on data from the TROPION-Breast02 phase III trial, which demonstrated that Datroway significantly improves median overall survival compared to traditional chemotherapy, indicating its potential to enhance patient survival rates.
- Priority Review Status: Datroway's new indication received Priority Review, which not only expedited its market entry but also reflects the FDA's recognition of the drug's importance in treating metastatic triple-negative breast cancer, potentially providing new options for patients.
- Market Impact and Outlook: With FDA approval, Datroway is poised to capture a significant share in the competitive oncology market, enhancing AstraZeneca's market position and revenue potential, thereby solidifying its leadership in the biopharmaceutical sector.
See More
AstraZeneca and Daiichi Sankyo Launch Datroway for TNBC Treatment
- FDA Approval: AstraZeneca and Daiichi Sankyo announced that Datroway (datopotamab deruxtecan) has received FDA approval for the treatment of metastatic triple-negative breast cancer (TNBC), marking a significant advancement in this area and is expected to substantially improve patient survival rates.
- Clinical Trial Results: The TROPION Breast 02 trial, involving 644 TNBC patients who were not candidates for PD-1/PD-L1 inhibitor therapy, demonstrated a clinically meaningful 5-month improvement in median overall survival following treatment with Datroway, indicating its efficacy in extending patient survival.
- Significant Market Potential: With 345,000 new cases of TNBC diagnosed globally each year, accounting for 15% of all breast cancer cases, the launch of Datroway provides a new treatment option for this large patient population, potentially leading to substantial market revenue.
- Future Development Directions: In addition to TNBC, Datroway is also being evaluated for efficacy in non-small cell lung cancer and urothelial cancers, showcasing its broad potential indications and further solidifying AstraZeneca's strategic positioning in the oncology treatment landscape.
See More
EU Drug Regulator Panel Endorses Eight New Medicines for Approval
- New Drug Approvals: The EU drug regulator's expert panel endorsed eight new medicines this week, including Merck's Keytruda and AstraZeneca's Enhertu, indicating a positive outlook for cancer treatment advancements that could enhance market performance for these companies.
- Maviret Indication Expansion: AbbVie announced that its antiviral drug Maviret received a positive opinion for use in patients aged three and older with acute hepatitis C, with final authorization expected by Q3 2026, thereby expanding its influence in the liver disease treatment market.
- Keytruda Combination Therapy: Merck's Keytruda was recommended for use in combination with Pfizer's Padcev for muscle-invasive bladder cancer that cannot be surgically removed, which is expected to enhance its competitive position in the oncology market, with a final decision anticipated by Q3 2026.
- Trodelvy Label Expansion: Gilead's Trodelvy received a positive opinion for treating adults with unresectable triple-negative breast cancer, with a final decision on the label expansion expected later this year, further solidifying Gilead's position in the oncology drug market.
See More
Biotech Sector Regulatory Approvals and Collaborations
- Kidney Cancer Treatment Breakthrough: HUTCHMED and Innovent received NMPA approval in China for the ELUNATE-TYVYT combination therapy, supported by the FRUSICA-2 study showing a 63% reduction in disease progression or death risk, with a median progression-free survival of 22.2 months, significantly improving patient outcomes and enhancing market competitiveness.
- Antibiotic Market Expansion: Sunshine Biopharma received Canadian approval for its generic Amoxicillin, with shipments expected to begin in August 2026, aiming to increase access to high-quality antibiotics for treating common infections, which is anticipated to drive revenue growth for the company.
- Liquid Biopsy Technology Innovation: Guardant Health gained FDA approval for Guardant360 Liquid CDx, now the largest liquid biopsy panel with a genomic footprint 100 times broader than its predecessor, enhancing tumor profiling capabilities and expected to boost the company's market share in precision medicine.
- New Hypertension Drug Launch: AstraZeneca received FDA approval for BAXFENDY for hypertension patients, based on positive results from the BaxHTN Phase III trial, which is expected to strengthen the company's competitive position in the cardiovascular drug market and further expand its product line.
See More
DATROWAY Approved for Treatment of Triple-Negative Breast Cancer
- Significant Survival Extension: In the TROPION-Breast02 Phase III trial, DATROWAY demonstrated an unprecedented median overall survival of approximately two years compared to chemotherapy, indicating its potential to become the new standard of care for patients with unresectable or metastatic triple-negative breast cancer.
- FDA Priority Review Approval: DATROWAY has been approved by the FDA as the first drug to significantly prolong survival in the first-line setting, providing a much-needed treatment option for patients who are not candidates for PD-1/PD-L1 inhibitor therapy, thus filling a critical gap in the market.
- Outstanding Clinical Trial Results: DATROWAY achieved a 64% objective response rate in clinical trials, significantly higher than the 30% seen with chemotherapy, while also reducing the risk of disease progression or death by 43%, establishing a strong foundation for its application in cancer treatment.
- Global Development Program: The global clinical development program for DATROWAY is underway, covering multiple cancer types, showcasing its broad application potential in oncology and further solidifying AstraZeneca and Daiichi Sankyo's leadership in the oncology drug market.
See More
